Drug Search Results

Racotumomab

Alternative Names: racotumomab
Latest Update: 2024-03-12
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Immunostimulant

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Chile

Approved Indications: None

Known Adverse Events: None

Company: Laboratorio Elea Phoenix
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Racotumomab

Countries in Clinic: Argentina

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Neuroblastoma

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
AR-RACO-2-16	P2	Completed	Neuroblastoma	2022-11-01	57%

Recent News Events

Date	Type	Title
03/12/2024	PubMed	Therapeutic vaccines for advanced non-small cell lung cancer.
12/08/2022	PubMed	GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype.
02/27/2020	News Article	$200B+ Cancer Immunotherapy Market Opportunity Insights, 2026 - Cancer Vaccines, Monoclonal Antibodies, Trials of T-Cell Therapies, Pipeline Overview, Competitive Landscape, and More
02/26/2020	News Article	Insights into the Global Cancer Immunotherapy Market to 2026 - Clinical Trials Insight by Phase, Company, Patient Segment and Drug Class - ResearchAndMarkets.com
02/26/2020	News Article	Global Cancer Immunotherapy Market Opportunity, Dosage, Price and Clinical Trials Insight 2020-2026

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions